Radius Health, Inc., a Cambridge, MA-based biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women’s health conditions, completed a $43m equity financing.
The round was led by F2 Biosciences III, L.P., with participation from existing investors Biotech Growth N.V., MPM Capital, Brookside Capital, MPM Bio IV NVS Strategic Fund and BB Biotech Ventures. In conjunction with the funding, Morana Jovan-Embiricos, PhD, Managing Partner at F2 Biosciences, and Owen Hughes, Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, will join Radius’ Board of Directors.
The company intends to use the capital for the continued advancement of its clinical development programs for its lead asset, BA058, a novel anabolic, bone-building compound for the treatment of patients with osteoporosis at high risk of fracture.
Led by Michael S. Wyzga, President & CEO, Radius Health develops BA058-SC, an injectable form of BA058, which is currently in a Phase 3 trial, and BA058-TD, which is in a Phase 2 trial studying the efficacy of delivering BA058 via a transdermal patch.